For further details see:
IDEAYA reports data from Phase 2 darovasertib + crizotinib combo study in uveal melanomaFor further details see:
IDEAYA reports data from Phase 2 darovasertib + crizotinib combo study in uveal melanomaMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...